| Prospective Evaluation of Response to Treatment in Younger Adult Patients (18-60 Years) With Acute Myeloid Leukemia (AML) | Midostaurin, Quizartinib | Phase 3 | Not yet recruiting | University Hospital, Toulouse | Nov 19, 2026 |
| A Post-Marketing Trial to Evaluate the Safety and Efficacy of Quizartinib in Chinese Participants With Newly Diagnosed FMS-like Tyrosine Kinase 3-internal Tandem Duplication [FLT3-ITD] (+) Acute Myeloid Leukemia (AML) | Quizartinib | Phase 4 | Not yet recruiting | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Nov 19, 2026 |
| Yangyin Qingfei Decoction for Radiation Pneumonitis Prevention | Nintedanib | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Zhejiang Chinese Medical University | Nov 17, 2026 |
| A Trial Evaluating Two Imetelstat Doses in Participants With Lower Risk Myelodysplastic Syndrome (MDS) | Motesanib | Phase 4 | Not yet recruiting | Geron Corporation | Nov 16, 2026 |
| A Multicenter, Randomized, Blinded, Placebo- and Active-Controlled Phase II Study to Evaluate the Efficacy and Safety of SYH9061 in Adult Patients With Idiopathic Pulmonary Fibrosis | Nintedanib | Phase 2 | Not yet recruiting | CSPC-NBP Pharmaceutical Co., Ltd. | Nov 12, 2026 |
| Phase 2 Evaluation of Recombinant Human Platelet-Derived Growth Factor-BB (rhPDGF-BB) Injection for the Treatment of Infraorbital Hollowing | Becaplermin | Phase 2 | Not yet recruiting | Lynch Regenerative Medicine | Nov 4, 2026 |
| Liver Transplantation Versus Conventional Medical Therapy for Low-Grade GEP-NET With Liver Metastases | Sunitinib | — | Enrolling by invitation | Chiyi Chen | Nov 3, 2026 |
| Maintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After Allo-SCT | Motesanib | Phase 1 | Not yet recruiting | University of Wisconsin, Madison | Nov 2, 2026 |
| Adebrelimab Plus Famitinib as Adjuvant Therapy in Non-pCR NSCLC | Famitinib | Phase 2 | Not yet recruiting | Ruijin Hospital | Oct 22, 2026 |
| Benmelstobart Plus Anlotinib Versus Sunitinib as First-Line Treatment for Advanced Non-Clear Cell Renal Cell Carcinoma | Sunitinib | Phase 3 | Active, not recruiting | Sun Yat-sen University | Oct 20, 2026 |
| Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of Cytarabine, Daunorubicin, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) | Quizartinib | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | Oct 7, 2026 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6088 in Patients With Advanced/Metastatic Solid Tumors | Regorafenib | Phase 1 / Phase 2 | Not yet recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | Oct 5, 2026 |
| First-Line Systemic Therapies in Advanced Renal Cell Carcinoma in Spain | Pazopanib, Sunitinib | — | Active, not recruiting | Bristol-Myers Squibb | Oct 1, 2026 |
| Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II Trial | Famitinib | Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | Sep 29, 2026 |
| Retlirafusp Alfa Combined With Famitinib, Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Unresectable Pancreatic Cancer | Famitinib | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Zhengzhou University | Sep 11, 2026 |
| Adebrelimab With Famitinib and Chemotherapy as Neoadjuvant Therapy for ESCC | Famitinib | Phase 2 | Recruiting | First Affiliated Hospital Xi'an Jiaotong University | Aug 31, 2026 |
| Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast Cancer | Regorafenib | Phase 2 | Not yet recruiting | Fujian Cancer Hospital | Aug 14, 2026 |
| A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer | Regorafenib | Phase 1 / Phase 2 | Not yet recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | Aug 6, 2026 |
| A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, Fluorouracil and Irinotecan | Regorafenib | Phase 3 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | Jul 28, 2026 |
| Venetoclax in Association With 3+7 and Midostaurin in FLT3-mutated Acute Myeloid Leukemia | Midostaurin | Phase 1 / Phase 2 | Not yet recruiting | University Hospital, Bordeaux | Jul 24, 2026 |
| IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer | Regorafenib | Phase 3 | Recruiting | Innovent Biologics (Suzhou) Co. Ltd. | Jul 23, 2026 |
| Antifibrotic Therapy Decision-Making in Pulmonary Fibrosis | Nintedanib | — | Not yet recruiting | Bristol-Myers Squibb | Jul 23, 2026 |
| Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome | Regorafenib | Phase 2 | Not yet recruiting | Xiang-Qian | Jul 9, 2026 |
| A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and Pimitespib | Regorafenib, Sunitinib | Phase 2 | Recruiting | GlaxoSmithKline | Jul 8, 2026 |
| Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis | Nintedanib | Phase 2 | Recruiting | Mannkind Corporation | Jul 1, 2026 |
| An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive Advanced Ovarian Cancer | Sunitinib | Phase 2 | Recruiting | Bai-Rong Xia | Jun 25, 2026 |
| Camrelizumab With Famitinib for Patients With Rare Head and Neck Malignancies | Famitinib | Phase 1 / Phase 2 | Recruiting | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Jun 23, 2026 |
| Camrelizumab Combined With Famitinib Malate and Chemotherapy for Treatment of Recurrent/ Metastatic Cervical Cancer | Famitinib | Phase 2 | Not yet recruiting | Hunan Cancer Hospital | Jun 4, 2026 |
| A Comparison of a Medication Adherence Platform (FORTISKAP™) vs. Usual Care in Subjects on Oral Medications for the Treatment of Interstitial Lung Disease, Sarcoid and Pulmonary Hypertension | Nintedanib | — | Not yet recruiting | Cosmos Rx, Inc | May 29, 2026 |
| Nintedanib With or Without Dextromethorphan in Patients With Idiopathic Pulmonary Fibrosis (IPF) | Nintedanib | Phase 2 | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | May 13, 2026 |
| Salvage Haploidentical HSCT With DLI and Targeted Therapy for R/R AML | Midostaurin | — | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | May 7, 2026 |
| Clinical Study of Novel Therapeutic Vaccine for Advanced Solid Tumors | Regorafenib | Phase 1 | Recruiting | West China Hospital | May 5, 2026 |
| Phase 2 Study Of Imetelstat for Patient With Myelodysplastic/Myeloproliferative Neoplasms | Motesanib | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | Apr 24, 2026 |
| Study of SA+X in the Treatment of Newly Diagnosed AML | Quizartinib | Phase 2 | Recruiting | Ruijin Hospital | Apr 23, 2026 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of HSK44459 Tablets in Patients With Idiopathic Pulmonary Fibrosis | Nintedanib | Phase 3 | Not yet recruiting | Haisco Pharmaceutical Group Co., Ltd. | Apr 9, 2026 |
| Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal Melanoma | Famitinib | Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | Apr 8, 2026 |
| Double Immunosuppression With or Without Anti-fibrotic in Scleroderma ILD | Nintedanib | — | Recruiting | University of Patras | Mar 24, 2026 |
| Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI) | Quizartinib | Phase 3 | Recruiting | PETHEMA Foundation | Mar 18, 2026 |
| A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma | Sunitinib | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | Mar 17, 2026 |
| A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical Cancer | Famitinib | Not applicable | Not yet recruiting | Jin LI | Mar 12, 2026 |
| A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas | Pazopanib | Phase 1 | Recruiting | M.D. Anderson Cancer Center | Mar 3, 2026 |
| FLT3-ITD Targeted Therapy in Fit AML Patients | Midostaurin, Quizartinib | Phase 2 / Phase 3 | Not yet recruiting | European Organisation for Research and Treatment of Cancer - EORTC | Feb 23, 2026 |
| Imetelstat Combinations in Relapsed AML | Motesanib | Phase 1 | Recruiting | Douglas Tremblay | Jan 6, 2026 |
| A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy | Sunitinib | Phase 3 | Recruiting | GlaxoSmithKline | Oct 21, 2025 |
| Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients | Masitinib | Phase 3 | Not yet recruiting | AB Science | Sep 16, 2025 |
| A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI | Sunitinib | Phase 3 | Not yet recruiting | Peking University Cancer Hospital & Institute | Sep 10, 2025 |
| A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma | Pazopanib | Phase 2 | Recruiting | Imbioray (Hangzhou) Biomedicine Co., Ltd. | Jul 25, 2025 |
| Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1) | Pazopanib | Phase 1 / Phase 2 | Recruiting | Tianjin Medical University Second Hospital | Mar 26, 2025 |
| Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission | Quizartinib | Phase 2 | Recruiting | Daiichi Sankyo | Feb 13, 2025 |
| Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or Adolescents | Pazopanib | Phase 2 | Recruiting | Shandong Cancer Hospital and Institute | Feb 10, 2025 |
| Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia | Quizartinib | Phase 1 | Recruiting | M.D. Anderson Cancer Center | Jan 10, 2025 |
| Fatty Liver and Pancreatic Steatosis | Becaplermin | — | Not yet recruiting | Maria Marta Piskorz | Jan 3, 2025 |
| Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion | Pazopanib | Phase 2 | Recruiting | Tianjin Medical University Second Hospital | Dec 18, 2024 |
| Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study) | Pazopanib | Phase 3 | Recruiting | Sun Yat-sen University | Dec 10, 2024 |
| Revumenib in Combination With 7+3 + Midostaurin in AML | Midostaurin | Phase 1 | Recruiting | Richard Stone, MD | Mar 15, 2024 |
| Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT) | Seralutinib | Phase 3 | Recruiting | Gossamer Bio USA, Inc. | Feb 23, 2024 |
| A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3) | Pazopanib | Phase 3 | Recruiting | Intensity Therapeutics, Inc. | Feb 16, 2024 |
| Multi-peptide Vaccination Adjuvanted With XS15 in Acute Myeloid Leukemia Patients | Midostaurin | Phase 1 | Recruiting | University Hospital Tuebingen | Feb 9, 2024 |
| A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy | Motesanib | Phase 1 | Recruiting | Children's Oncology Group | Feb 8, 2024 |
| Masitinib in Patients With Mild Alzheimer's Disease | Masitinib | Phase 3 | Not yet recruiting | AB Science | Oct 3, 2022 |
| Rh-PDGF vs EMD for Treatment of Intra-bony Defects | Becaplermin | Phase 1 / Phase 2 | Recruiting | Nova Southeastern University | Jul 1, 2022 |
| A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis | Motesanib | Phase 1 | Active, not recruiting | Geron Corporation | May 12, 2022 |
| Ridge Augmentation Using Allograft Particles Hydrated With or Without Recombinant Human Platelet-Derived Growth Factor | Becaplermin | Not applicable | Recruiting | University of Alabama at Birmingham | Jul 8, 2021 |
| Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML) | Midostaurin | — | Recruiting | Acute Leukemia French Association | Mar 2, 2021 |
| Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents | Cediranib | Phase 2 | Active, not recruiting | National Cancer Institute (NCI) | Feb 5, 2021 |
| A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment | Motesanib | Phase 3 | Active, not recruiting | Geron Corporation | Oct 6, 2020 |
| A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical Cancer | Cediranib | Phase 2 | Active, not recruiting | The Clatterbridge Cancer Centre NHS Foundation Trust | Jul 27, 2020 |
| Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) | Midostaurin | Phase 1 / Phase 2 | Recruiting | Technische Universität Dresden | May 12, 2020 |
| Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer | Cediranib | Phase 2 | Recruiting | M.D. Anderson Cancer Center | Sep 16, 2019 |
| Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors | Cediranib | Phase 2 | Active, not recruiting | University Health Network, Toronto | Feb 22, 2019 |
| WIRE - Novel Treatments in Renal Cell Cancer | Cediranib | Phase 2 | Recruiting | CCTU- Cancer Theme | Nov 14, 2018 |
| Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone | Cediranib | Phase 2 | Active, not recruiting | National Cancer Institute (NCI) | Sep 7, 2018 |
| Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy | Cediranib | Phase 2 | Active, not recruiting | AstraZeneca | Nov 7, 2017 |
| Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients | Masitinib | Phase 3 | Recruiting | AB Science | Apr 25, 2017 |
| Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma | Cediranib | Phase 2 | Active, not recruiting | National Cancer Institute (NCI) | Nov 28, 2016 |
| Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) | Motesanib | Phase 2 / Phase 3 | Active, not recruiting | Geron Corporation | Nov 6, 2015 |